Pharmaceutical companies Sanofi and Teva have reported positive results from trial tests of their joint drug for Ulcerative Colitis and Crohn's disease. This puts them in line for creating a possible 'best in class' drug for bowel diseases. Also, aficamten, a heart disease medication initially developed by Cytokinetics has been purchased by Sanofi for development and commercialisation in Greater China. However, this decision is pending approval. Legal actions have been instigated by Sanofi against the HHS in defence of 340B rebates policy.
Moving forward, Sanofi is giving due consideration towards altering its hospital drug-discount plan which has earned them a threatened sanction from the federal government. Amidst trade tensions between the European Union and China, Sanofi announces its largest investment deal. The company's anti-inflammatory drug, developed in collaboration with Teva, has shown considerable promise for treating bowel diseases.
Sanofi News Analytics from Thu, 21 Mar 2024 07:00:00 GMT to Sat, 21 Dec 2024 11:28:58 GMT - Rating 7 - Innovation 8 - Information 9 - Rumor 5
